Antibody buffering in the brain

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• The blood-brain barrier restricts chemotherapy drug entry into cerebrospinal fluid (CSF), limiting brain tumor treatment efficacy.
• Achieving sustained therapeutic drug concentrations in the CSF for slow-growing tumors is challenging due to rapid drug elimination.

Purpose of the Study:

• To investigate antibody buffering as a method to prolong drug half-life and bioactivity within the CSF.
• To assess the feasibility of in situ recharging of antibody-buffered drugs in the CSF.

Main Methods:

• Antibody buffering of a small molecule hapten (2-phenyl-oxazol-5-one-methylene-gamma-amino butyrate) was performed in rat CSF.
• Half-life of total and free hapten was measured in the presence of the antibody buffer.
• In situ recharging of the antibody buffer with fresh hapten was evaluated.

Main Results:

• Antibody buffering significantly increased the half-life of both total and free hapten in the CSF.
• The antibody buffer demonstrated the ability to be re-charged in situ with fresh hapten days after initial administration.

Conclusions:

• Antibody buffering is a promising strategy to enhance drug delivery and prolong therapeutic effects within the CSF.
• This approach may overcome challenges associated with rapid drug elimination, offering a viable option for brain tumor chemotherapy.